Back
Our Bureau New Delhi, May 21 Pharma-major Ranbaxy Laboratories Ltd on Wednesday said it has commenced its operations in Yemen, strengthening its presence in the West Asian region. Ranbaxy has tied up with Pharma Ltd (Natco) as business partners for its Yemen operations. Ranbaxy will focus on therapy areas such as anti-infectives, gastro-intestinal, cholesterol lowering and anti-allergic categories in Yemen. Commenting on the launch, Mr Sanjeev I. Dani, Senior Vice-President & Regional Director — Asia & CIS, Ranbaxy, said, “Yemen is an important market for us. Our endeavour is to bring down the health care cost in Yemen by providing value-added international quality products at affordable prices.” With this the company will have presence in 11 countries in the West Asian region where it has a strong product pipeline with 160 approvals. “UAE is the single largest market for the region where Ranbaxy enjoys the distinction of being the largest generic company with 20 products. Two of them feature among the top 50 pharmaceutical products in UAE. Ranbaxy is ranked 12th and also the fastest growing amongst the Top 15 pharmaceutical companies in UAE including the originators. In Oman, Ranbaxy is the No.1 company in the private sector for the past three years,” said a press release. © Copyright 2000 - 2009 The Hindu Business Line |